May's edition of the EJHP includes an editorial on change blindness as well as original articles on individualised antimicrobial dosing in critically ill patients undergoing continuous renal replacement therapy, on the evaluation of the physicochemical and biological stability of reconstituted and diluted SB2 (infliximab) and on the impact of fampridine on quality of life. More information on the rapid acting fentanyl formulations in breakthrough pain in cancer can be found on the electronic pages of the EJHP May issue.

Read the EJHP May edition HERE